Streptokinase

PreclinicalProtein / enzyme

Boehringer Ingelheim

Streptokinase is one of 27 small molecule programs targeting Pulmonary Embolism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismActive, not recruiting

Pulmonary EmbolismPreclinical

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Activase

Roche

Approved

7 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

1 4

Innohep

Jazz Pharmaceuticals

Approved

1 5

Xarelto

WWim Janssens

Approved

8 6

Coumadin

AAbbott

Approved

6 7

Savaysa

Voltaren

Opsumit

Pradaxa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Not yet recruiting

Pulmonary Embolism

NCT06545864

Clinical

Trials by Indication[1]

Acute Myocardial Infarction3 trials

Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction

Completed·IIstanbul University·Phase 4·NCT00627809·53 enrolled

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02182011·49 enrolled

Intravenous Streptokinase in Acute Myocardial Infarction

Completed·UUniversity of Washington·Phase 3·NCT00000507

Pulmonary Embolism2 trials

Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism

Not yet recruiting·—··NCT06545864·50 enrolled

Catheter Directed Interventions in Pulmonary Embolism

Unknown status·—·N/A·NCT03595085·60 enrolled

Prosthetic Valve Thrombosis2 trials

To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis

Completed·—·N/A·NCT07360717·100 enrolled

Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

Completed·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT01451320·182 enrolled

Trial2 trials

Asia Africa Streptokinase Trial

Withdrawn·UUniversity of Alberta·Phase 2·NCT02150785

A Trial Using Double-Bolus THR-100 Versus Streptokinase

Completed·BBharat Biotech International Limited·Phase 3·NCT01305226·120 enrolled

Nebulization1 trial

Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS

Completed·—·Phase 3·NCT03465085·60 enrolled

4 more indications

Completed·—·Phase 3·NCT00232622·120 enrolled

Unspecified1 trial

Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital

Unknown status·—·Phase 4·NCT03172052·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Streptokinase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Streptokinase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Streptokinase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Streptokinase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Acute Myocardial Infarction3 trials

Pulmonary Embolism2 trials

Prosthetic Valve Thrombosis2 trials

Trial2 trials

Nebulization1 trial

Clinical Trial1 trial

Necrosis1 trial

Heart1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News